StreetInsider.com News Articles

Raymond James Downgrades CIGNA (CI) to Outperform

Mon, 03 Aug 2026 07:20:19 -0400

Raymond James analyst John Ransom downgraded CIGNA (NYSE: CI) from Strong Buy to Outperform with a price target of $320.00 (from $350.00).

The analyst comments "We are downgrading our rating on CI to Outperform while lowering our price target to $320 (~8.5x 2028E EPS). The reasons for the downgrade are as follows: 1) We view CI as a slower growth name operating in a mature market, and see more attractive upside at other names in our coverage. 2) We don’t see a clear catalyst over the next 6-12 months that would support our prior Strong Buy rating. And 3) the PBM

Raymond James Downgrades CIGNA (CI) to Outperform

Mon, 03 Aug 2026 07:20:19 -0400

Raymond James analyst John Ransom downgraded CIGNA (NYSE: CI) from Strong Buy to Outperform with a price target of $320.00 (from $350.00).

CIGNA (CI) PT Raised to $307 at Wells Fargo

Fri, 31 Jul 2026 08:35:50 -0400

Wells Fargo analyst Stephen Baxter raised the price target on CIGNA (NYSE: CI) to $307.00 (from $305.00) while maintaining a Equal Weight rating.

CIGNA (CI) PT Raised to $361 at Guggenheim

Fri, 31 Jul 2026 07:47:09 -0400

(Updated - July 31, 2026 7:47 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on CIGNA (NYSE: CI) to $361.00 (from $338.00) while maintaining a Buy rating.

The analyst commented: "CI reported 2Q26 EPS upside from another quarter of Specialty & Care strength (accelerated biosimilars + generic conversions) combined with favorable cost trend development within Healthcare (outpatient). As a partial offset, CI’s PBM realized slight headwinds from GLP-1 moderation + the loss of related generic conversion economics, even though the latter still develops as a positive for the overall Evernorth franchise. Net-net, investors likely wanted to see more pull-through to

CIGNA (CI) PT Raised to $361 at Guggenheim

Fri, 31 Jul 2026 07:47:09 -0400

(Updated - July 31, 2026 7:47 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on CIGNA (NYSE: CI) to $361.00 (from $338.00) while maintaining a Buy rating.

CIGNA (CI) PT Raised to $362 at Baird

Fri, 31 Jul 2026 07:18:58 -0400

Baird analyst Michael Ha raised the price target on CIGNA (NYSE: CI) to $362.00 (from $337.00) while maintaining a Outperform rating.

CIGNA (CI) PT Raised to $310 at Barclays

Fri, 31 Jul 2026 06:12:01 -0400

Barclays analyst Andrew Mok raised the price target on CIGNA (NYSE: CI) to $310.00 (from $304.00) while maintaining a Equalweight rating.

Form 10-Q Cigna Group For: Jun 30

Thu, 30 Jul 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260730/26841922.html

Form 10-Q Cigna Group For: Jun 30

Thu, 30 Jul 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260730/26841922.html

Cigna beats Q2 estimates, lifts earnings guidance

Thu, 30 Jul 2026 06:50:38 -0400

Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.

The health company posted adjusted earnings of $7.78 per share for the second quarter, beating the analyst consensus of $7.59 by $0.19. Revenue increased 7% YoY to $71.7 billion, surpassing the $70.18 billion estimate.

The company raised its full-year 2026 adjusted earnings outlook to at least $30.45 per share, up $0.10 from its prior projection and slightly above the analyst consensus of $30.41.

The revenue growth was driven by increases in both the

Cigna beats Q2 estimates, lifts earnings guidance

Thu, 30 Jul 2026 06:50:38 -0400

The company raised its full-year 2026 adjusted earnings outlook to at least $30.45 per share, up $0.10 from its prior projection and slightly above the analyst consensus of $30.41.

The revenue growth was driven by increases in both the

Form 8-K Cigna Group For: Jul 30

Thu, 30 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260730/26838024.html

Form 8-K Cigna Group For: Jul 30

Thu, 30 Jul 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20260730/26838024.html

Cigna Corp. (CI) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance

Thu, 30 Jul 2026 06:04:07 -0400

Cigna Corp. (NYSE: CI) reported Q2 EPS of $7.78, $0.19 better than the analyst estimate of $7.59. Revenue for the quarter came in at $71.7 billion versus the consensus estimate of $70.18 billion.

GUIDANCE:

Cigna Corp. sees FY2026 EPS of $30.45, versus the consensus of $30.41.